↓ Skip to Main Content

the new generation glocalized patient network in theragenomic and personalized medicine and individualized drug safety

search: thasso

Search for:

Log in

Main Navigation

english
thasso
thasso post
thasso community
thasso toolbox
thasso academy
thasso – about
donations $

Home › Posts tagged Acute Lymphoblastic Leukemia (ALL)

Tag: Acute Lymphoblastic Leukemia (ALL)

Besponsa: Is this really a viable new treatment for ALL?

By Joseph Gut - thasso Posted on August 18, 2017 Posted in New Drug Approval, Targeted Therapy, Thasso Post, Theragenomic Medicine No Comments Tagged with Acute Lymphoblastic Leukemia (ALL), American Food & Drug Administration (FDA), Antibody-Drug Conjugate (ADC), B-cell Precursor, Calicheamicin, CD22, Cytotoxic, European Medicines Agency (EMA), Inotuzumab Ozogamicin (Besponsa), Targeted Therapy, Thasso Post, Theragenomic Medicine

Besponsa: Is this really a viable new treatment for ALL?

August 18, 2017 – B-cell precursor acute lymphoblastic leukemia (ALL) is a aggressive and rapidly progressing type of cancer in which the bone marrow makes too many B-cell lymphocytes, an immature type of white blood cell. In the United States, …

Besponsa: Is this really a viable new treatment for ALL? Read more »

Inherited risk factors increase odds of developing childhood acute lymphoblastic leukemia (ALL)

By Joseph Gut - thasso Posted on January 16, 2010 Posted in Genetic Predisposition, Genetic Susceptibility, Personalized Medicine, Pharmacogenetics No Comments Tagged with Acute Lymphoblastic Leukemia (ALL), Allelic Variants, ARID5B, IKZF1, ScienceBlog, Single Nucleotide Polymorphisms (SNPs)

January 16, 2010 – This contribution has just been published in the ScienceBlog – Pharmacogenetics at this locoation. It is presented here in its original state and with all credentials and rights resting with the original author. Scientists at St. …

Inherited risk factors increase odds of developing childhood acute lymphoblastic leukemia (ALL) Read more »

Optional: Social Subscribe/Login

thasso: donate

We need your help. Please support the development of thasso through donations. Thank you. Nous avons besoin de votre aide. S'il vous plaît, vous pouvez soutenir le développement de thasso grâce à des dons. Merci. Wir brauchen Ihre Hilfe. Bitte unterstützen Sie die Entwicklung von thasso durch Spenden. Vielen Dank.

thasso: conditions

thasso: newest tweets

Tweets by thasso_info

FDA press releases

Coronavirus (COVID-19) Update: FDA Takes Additional Actions on the Use of a Booster Dose for COVID-19 Vaccines October 20, 2021
Federal Judge Enters Consent Decree with Utah-based Dietary Supplement Manufacturer October 20, 2021
Coronavirus (COVID-19) Update: October 19, 2021 October 19, 2021
FDA Permits Marketing of New Oral Tobacco Products through Premarket Tobacco Product Application Pathway October 19, 2021
FDA Issues Landmark Proposal to Improve Access to Hearing Aid Technology for Millions of Americans October 19, 2021

FDA MedWatch

Merck Issues Voluntary Nationwide Recall of CUBICIN® (Daptomycin for Injection) 500 mg, Lot 934778, Due to Presence of Particulate Matter Identified as Glass Particles October 20, 2021
Bryant Ranch Prepack Issues Voluntary Nationwide Recall of Methocarbamol 500mg Bottles Due to Mislabeling With the Incorrect Strength October 19, 2021
Cook Medical Issues Voluntary Recall of Transseptal Needle and Transseptal Needle with Catheter October 19, 2021
All Ultrasound Gels and Lotions Manufactured by Eco-Med Pharmaceutical, Inc. Recalled Due to Risk of Bacteria Contamination October 18, 2021
Abbott Molecular, Inc. Recalls Alinity m SARS-CoV-2 AMP Kit and Alinity m Resp-4-Plex AMP Kit for Potential False Positive SARS-CoV-2 Test Results October 15, 2021

EMA Press releases

EMA starts evaluating use of COVID-19 vaccine Comirnaty in children aged 5 to 11, CHMP, 18/10/2021 October 18, 2021
New manufacturing sites and new formulation approved for COVID-19 vaccine from BioNTech/Pfizer, CHMP, 18/10/2021 October 18, 2021
First-in-class medicine to treat aggressive form of breast cancer, CHMP, 15/10/2021 October 15, 2021
Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 11-14 October 2021, CHMP, 15/10/2021 October 15, 2021
EMA starts rolling review of Evusheld (tixagevimab and cilgavimab), CHMP, 14/10/2021 October 14, 2021

random genetics

Genetic testing of the siblings of newborns with cancer genes could reduce rare pediatric cancer deaths by half October 19, 2021
Genetic testing of the siblings of newborns found to have mutations in any one of 11 genes most commonly associated with childhood-onset cancers could reduce deaths from these rare cancers by about 50%, suggests a study funded by the National Institutes of Health. Moreover, such routine testing could save nearly $17,000 per year for each […]
Nudging cells to repair damaged retinas October 19, 2021
In an approach could someday be used to help repair the retinas in patients who have lost vision due to such diseases as macular degeneration, glaucoma and diabetes, scientists at the University of Washington School of Medicine in Seattle have induced non-neuronal cells to become retinal neurons.
Genomic study revealing among diverse populations with inherited retinal disease October 19, 2021
An international team of researchers, led by scientists at University of California San Diego and Shiley Eye Institute at UC San Diego Health, has broadened and deepened understanding of how inherited retinal dystrophies (IRDs) affect different populations of people, and in the process, have identified new gene variants that may cause the diseases.
A global effort to understand why some people are resistant to SARS-CoV-2 infections October 19, 2021
An international team of medical scientists has published a Perspective piece in the journal Nature Immunology, outlining ongoing research into why some people are resistant to SARS-CoV-2 infections. In their paper, they note that very little is currently known about why some individuals are immune to COVID-19, but they suggest that a stronger effort to […]
Largest ever global study of tuberculosis identifies genetic causes of drug resistance October 19, 2021
Using cutting-edge genomic sequencing techniques, researchers at the University of Oxford have identified almost all the genomic variation that gives people resistance to 13 of the most common tuberculosis (TB) drug treatments.

Recent Comments

David Walliams on Is genetic testing of value for ALS patients?: “CURED FROM GENITAL HERPES More than 5 years ago I was in pain with this deadly herpes virus, A few…” Nov 7, 16:08
Raul Malkovic on Is genetic testing of value for ALS patients?: “HOW MY WIFE GOT CURED FROM ALS Below is how i got a cure for my wife who suffered from Amyotrophic Lateral Sclerosis…” Nov 6, 21:18
Pamela Erickson on Is genetic testing of value for ALS patients?: “My husband was diagnosed with ALS (amyotrophic lateral sclerosis) when he was 63 years old 4 years ago. The Rilutek…” Aug 13, 13:04
thassodotcom on Unlucky women with BIA-ALCL: An update: “The Therapeutic Goods Agency (TGA) of Australia has just issued a hazard alert concerning the risk of breast implant-associated anaplastic…” Aug 4, 09:17
thassodotcom on Tofacitinib (Xeljanz): Dangers of blood clots in the lungs and of death: “According to its Drug Safety Communication from 07/26/2019, the FDA has approved new warnings about an increased risk of blood…” Aug 4, 08:40

Tag Cloud

African American Allelic Variant American Food & Drug Administration (FDA) American Food & Drug Administration (FDA) Boxed Warning Breast Cancer Canagliflozin (Invokana) Cancer Children Committee for Medicinal Products for Human Use (CHMP) Companion Test Covid-19 Disease Diabetes Drug Induced Liver Injury (DILI) Empagliflozin [Jardiance] Epidermal Growth Factor Receptor (EGFR) Ethnicity European Medicine Agency (EMA) European Medicines Agency (EMA) Food and Drug Administration (FDA) Gene Therapy Genetic Background Genetic Predisposition Genetic Testing Health Canada Non-Small Cell Lung Cancer (NSCLC) Obesity Pembrolizumab [Keytruda] Personalized Medicine Phenotype Progressive Multifocal Leukoencephalopathy (PML) Rare Disease Risk Evaluation and Mitigation Strategy (REMS) SARS-CoV-2 Schizophrenia Sildenafil [Viagra] Sodium-Glucose Cotransporter-2 (SGLT2) Stevens Johnson Syndrome [SJS] Targeted Therapy ThassoBase Thasso Post Theragenomic Medicine Toxic Epidermal Necrolysis (TEN) Type 2 Diabetes Vemurafenib [Zelboraf]

thasso

thasso, the new generation glocalized patient network in theragenomic and personalized medicine and individualized drug safety provides access to and sharing of personal and professional information in health and disease to individual patients, to patient subgroups, and to large patient populations worldwide

keys

Social Media, Social Network, Theragenomic Medicine, Social Medicine, Personalized Medicine, Genomic Medicine, Participative Medicine, Targeted Therapy, Individualized Therapy, Personalized Therapy, Individualized Drug Safety, Personalized Drug Safety, Genetic Variants, Allelic Variants, Genotypes, Molecular Phenotypes, Clinical Phenotypes, Companion Test, Heart Disease, Arthritis, Asthma, Diabetes, Hypertension, Malignant Tumors, Breast Cancer, Lung Cancer, Skin Cancer, Erectile Dysfunction, Crowd Sourcing, Patient Sourcing, Participative Sourcing, Collective Experience, Collective Community Wisdom, Apomediary Patient Expert, Patient Cloud,

meta

Register
Log in
Entries feed
Comments feed
WordPress.org

© 2021 thasso | Powered by Responsive Theme